A new study has raised concerns about the potential link between glucosamine, a common joint supplement, and increased Alzheimer’s risk, though researchers caution the findings do not prove causation. The research, conducted by a team at a German university, analyzed data from over 10,000 participants and found an association between long-term glucosamine use and faster cognitive decline in individuals with early-stage Alzheimer’s, according to the study authors.
What the Study Found
The observational study, published in a peer-reviewed journal, tracked participants over five years and noted that those who regularly took glucosamine supplements experienced a 25% faster decline in memory and executive function compared to non-users. The effect was most pronounced in individuals already diagnosed with mild cognitive impairment. Researchers emphasized the data does not confirm glucosamine causes cognitive decline but suggests a possible correlation that warrants further investigation.
Who Is Most Affected
The study focused on adults aged 65 and older, a demographic already at higher risk for Alzheimer’s. Among participants with a genetic predisposition to the disease, the observed memory decline was more significant. However, the researchers noted that the sample size for this subgroup was relatively small, limiting the strength of conclusions about genetic interactions.
Limitations and Unanswered Questions
Experts highlight several limitations of the study, including its observational design, which cannot establish a direct cause-and-effect relationship. Confounding factors, such as the underlying health conditions of participants or concurrent use of other medications, were not fully accounted for. Additionally, the study did not differentiate between oral glucosamine supplements and other forms of the compound, such as those used in topical treatments.
What Experts Recommend
Health officials advise patients to continue following their healthcare provider’s recommendations for managing joint pain and Alzheimer’s risk. “This study adds to a growing body of research but does not change current guidelines,” said a spokesperson for a national Alzheimer’s association. “People should not stop or start supplements without consulting their doctor.”
Researchers plan to conduct larger, randomized trials to explore the relationship between glucosamine and cognitive health. Until then, the study underscores the importance of cautious interpretation of observational data in public health messaging.
